Changpeng Zhao Intends To Invest Crypto in Biotech to Foster Research

• Changpeng Zhao shared his enthusiasm for exploring the wider space of DeSci.
• According to a tweet, Binance’s former CEO intends to invest crypto in biotech, fostering research.
• Messari CEO Ryan Selkis and the Etica protocol acknowledged Zhao’s interest in DeSci.

Changpeng Zhao, the former CEO of Binance, has hinted at his initiative to explore the wider space of decentralized science (DeSci). In his recent tweet, Zhao unveiled his thoughts on the ways in which crypto and biotechnology could go hand in hand.

Shedding light on his potential step to invest cryptocurrencies in biotechnology to “accelerate funding” in biotech research, the former Binance CEO signaled his future plans following his departure from Binance.

Zhao’s enthusiasm for collaborating in crypto with biotech has received great acceptance from both spaces. Etica, the protocol that supports open-source research in DeSci, shared their immense pleasure in witnessing major crypto figures stepping into the DeSci space.

They cited, “We are glad seeing others in the crypto industry start connecting the dots to biotech, research, and DeSci at large.”

Similarly, Ryan Selkis, the CEO of the crypto market aggregator Messari, responded to Zhao’s tweet, acknowledging the latter’s interest in the evolving DeSci arena. DeSci is an aspect of the DeFi space that aims to create public infrastructure for science, leveraging blockchain technology.

The tweet came following a series of disquieting incidents involving Binance and Zhao. After a long period of regulatory challenges, including the Securities and Exchange Commission’s (SEC) lawsuit, Zhao pleaded guilty and submitted his resignation.

While the SEC sued Binance and Zhao for operating an unlicensed company and offering an illegal sale of securities, Zhao’s guilty plea admitted to violating anti-money laundering laws.